Tumor necrosis factor alpha (TNF-α) is a leading inflammatory cytokine that plays a pivotal role in the pathogenesis of psoriasis. In case of a severe course of psoriasis and moderate-to-severe disease in which traditional systemic treatments are ineffective or contraindicated, TNF-α inhibitors 
| INTRODUCTION
Tumor necrosis factor alpha (TNF-α) is a leading inflammatory cytokine that plays a pivotal role in the pathogenesis of psoriasis. It acts synergistically with other cytokines to activate lymphocytes Th1 and Th17, which resulted in the inflammatory cascade leading to premature maturation of keratinocytes responsible for the development of psoriatic lesions (De Simone et al., 2013) .
In case of a severe course of psoriasis systemic therapies are used, including monoclonal antibodies. Clinical studies showed that anti-TNF-α monoclonal antibodies are highly effective as 71-80% of patients using adalimumab have reached PASI75 within merely 16 weeks (Menter, Gordon, Leonardi, Gu, & Goldblum, 2010; Yamauchi, Bissonnette, Teixeira, & Valdecantos, 2016 ).
Yet, some patients remain unresponsive (primary drug failure) or their initially satisfactory response fades (secondary drug failure) (Yamauchi et al., 2016) . Anti-TNF therapy is withdrawn for an unsatisfactory response or its side effects in 30% of patients every year (Paccou et al., 2011 ).
| The safety of therapy
The presence of anti-drug antibodies (ADAs), neutralizing in particular, may increase the risk of adverse effects such as hypersensitivity reaction during infliximab infusion (De Simone et al., 2013; Schellekens, 2010) . Moreover, IgG-mediated ADAs may cause an IgE-independent anaphylactic reaction by activating the complement system (Sethu et al., 2012) . Other adverse effects stemming from the formation of immune complexes include serum sickness, Arthus reaction, bronchoconstriction, or thromboembolic events (Jani, Barton, Warren, Griffiths, & Chinoy, 2014) .
| The immunogenicity of TNF-α inhibitors
Immunogenicity is defined as the ability of a particular substance to induce a humoral or cell-mediated immune response. A drug may evoke such response based on its exogenous structure that may look foreign with respect to natural proteins of the body (De Simone et al., 2013; Schellekens, 2010) . The organism's immune system can detect the smallest difference in the molecular structure of an exogenous substance and give rise to the production of antibodies (IgG4 class, predominantly) which lead to activation of complement system and/or phagocytosis in order to eliminate them (De Simone et al., 2013; Sethu et al., 2012) . The research of Menting et al. has shown that ADAs are produced within weeks from the start of therapeutic drug administration. Ninety percentage of patients treated with TNF-α inhibitors had detected ADAs within 24 weeks from the start of the therapy (Menting et al., 2014 ).
| Drug structure
Any drug that has a structure of a protein (whether entirely human antibodies, chimeric, or humanized antibodies) conveys unique sequences that may evoke immunologic response and the formation of anti-drug antibodies. ADAs can be directed against the therapeutic antibody's allotypic variation (difference in the light chain and heavy chain constant region) or against specific epitopes of idiotypic difference (variation in the variable region). This is why in a single patient we can find various types of ADAs that target various regions of the same therapeutic drug (Bendtzen, 2012; De Simone et al., 2013) . In such case the amount of free drug molecules that have remained capable of binding TNF-α may be significantly diminished, which brings about a change in the drug pharmacokinetics and pharmacodynamics (Jullien, Prinz, & Nestle, 2015) .
The drug molecular structure remains at the forefront of its potential immunogenicity. A chimeric drug like infliximab could induce antibody production directed against the Fab fragments being of murine origin, while entirely human adalimumab could induce antibody production against the epitopes of variable region (Anderson, 2005; De Simone et al., 2013 ).
| Treatment regimen
The immunization risk depends on the drug dose (thus its concentration in plasma), route, and frequency of administration as well as duration of treatment. Interestingly, a lower dose with interrupted administration is more immunogenic than a sustained administration of a higher dose (Christophers, Segaert, Milligan, Molta, & Boggs, 2013; De Simone et al., 2013; Parenky et al., 2014; Sethu et al., 2012) . In some countries, the national fund reimburses iTNF-α treatment for a specific time of therapy. For example, in Poland, the time of reimburse for adalimumab is 48 weeks, for infliximab is 96 weeks, and for etanercept fusion protein is only 24 weeks, regardless of the improvement after therapy. This results in a significant reduction in the effectiveness of treatment when the iTNF-α therapy is restarted.
Intravenous administration is regarded as less immunogenic than subcutaneous route that involves antigen presentation (Schellekens, 2010) . The biodistribution and clearance of therapeutic proteins in vivo also affect the risk of immunogenicity. Subcutaneous and intramuscular administration causes accumulation of the drug at the injection site, slows its clearance and formation of protein aggregates in comparison to intravenous and intraperitoneal administration. Therefore aggregates may have more than just intravenous injection. Higher dose and injection into the blood stream may be removed by the reticuloendothelial system in the spleen more effectively (Kijanka, Prokopowicz, Schellekens, & Brinks, 2014) . Consequently, European Medicines Agency recommends a sustained therapy (Lambert, Nast, Nestle, & Prinz, 2015) .
| Other factors
Immunogenicity depends on various factors including patient's individual susceptibility (genetic predisposition) or type of pathology during treatment (De Simone et al., 2013) . Bartels et al. revealed higher tendency to immunogenecity and ADAs formation against adalimumab in rheumatoid arthritis patients, associated with lower adalimumab concentration and lower likelihood of minimal disease activity or clinical remission (Bartelds et al., 2011 ).
| Types of anti-drug antibodies
Antibodies produced in response to monoclonal therapeutic antibodies can be neutralizing or non-neutralizing (Lambert et al., 2015; Schellekens, 2010; van Schouwenburg et al., 2013) . The former attach directly onto the binding site of the therapeutic antibody and correlates with the capacity of the therapeutic antibody to bind its target, thus neutralizing its therapeutic activity. The latter attach to the therapeutic antibody in the region that is not crucial for its therapeutic activity, which somewhat preserves its function (Schellekens, 2010;  van Schouwenburg et al., 2013) . The neutralization process is behind the hindered clinical response to treatment (Table 1) In case of fusion proteins like etanercept, produced ADAs are non-neutralizing as they attach to epitopes other than the TNF-α binding site. Although ADAs were present in as many as 18% of psoriasis patients receiving etanercept, it had no clinical significance (Tyring et al., 2007) . 1.7 | Impact on efficacy of therapy
The use of infliximab in the treatment of rheumatoid arthritis or ankylosing spondylitis evoked the production of ADAs in 19-26% patients, which was associated with drug's low plasma levels and poor clinical response (De Simone et al., 2013; Plasencia et al., 2012) . The same was observed when rheumatoid arthritis was treated with adalimumab but ADAs were produced in 28% of cases (Bartelds et al., 2011) . Similarly, in patients with severe plaque psoriasis ADAs increased in lower dose (3 mg/kg) and interrupted regimens comparison worth higher drug dose (5 mg/kg) and continuous therapy (Menter et al., 2007) .
Some clinical studies have revealed a decline in efficacy of anti-TNF-α therapy when used intermittently. The proportion of patients that reach PASI75 after treatment is expected to be lower by 11%
between weeks 24 and 108 during treatment with adalimumab (Papp, Menter, Poulin, Gu, & Sasso, 2013) , by 12% between weeks 48 and 96 with etancercept (Tyring et al., 2007) and by 23% between weeks 10 and 50 when treated with infliximab (Menter et al., 2007; Strober et al., 2011) . The appearance of anti-nuclear antibodies (ANA), anti-dsDNA in particular, during treatment with iTNF is an indirect indication of immunization process, which is a common finding during a secondary drug failure, yet without excluding the potential for response (Lambert et al., 2015; Pink, Fonia, Allen, Smith, & Barker, 2010) . In a study of Pink et al., a total of 97 patients showed no response after treatment with three different anti-TNF biologic drugs. After one, two, and eventually all three drugs have failed, the anti-nuclear antibodies were detected in 54%, 78%, and 83% of patients, respectively (Pink et al., 2010 ).
| Possible causes of drug secondary failuresummary
• Insufficient drug levels in plasma (obesity).
• Dose is too low.
• Immunogenicity (anti-drug antibodies), intermittent therapy or incidental drug administration (memory cells, drug-ADAs immune complexes acting as neoantigens).
1.9 | Actions that decrease immunogenicity 1.9.1 | Increase anti-TNFα drug dose or administration frequency
Boosting the drug dose or decreasing the intermittence in therapy increases the efficacy of treatment, yet with more financial cost (Lambert et al., 2015) . Humira may be recommended that a MTX adjuvant was used in every patient receiving TNF inhibitors (Zisapel et al., 2015) .
| Measurement of ADAs and trough serum drug levels
Measurement of ADAs and trough serum drug levels may help to make a proper decision regarding the treatment (Bracke & Lambert, 2013) .
Routine ADAs level measurements remain out of reach for both clinical practice and patients in which TNF inhibitors fail. ELISA is used in clinical studies. Yet, despite high sensitivity, the test is not very specific and often gives false positive results. ADAs may be estimated also with a radioimmunoassay but the use of radiation is a drawback itself (De Simone et al., 2013) . In turn, the estimation of trough serum drug levels correlates positively with clinical response and the trough levels are significantly lower in patients with ADAs (Lambert et al., 2015; Takahashi, Tsuji, Ishida-Yamamoto, & Iizuka, 2013 ; Figure 1 ).
| Switching of drug
In order to maximize patient response and avoid extra immunization clinical algorithms are being developed. For instance, Takahashi et al. pointed that measuring serum adalimumab level after 4 weeks of treatment may be used in predicting patient's response (Takahashi et al., 2013) .
Recently, a novel anti-TNF-α drug-certolizumab pegol-has been registered for the treatment of psoriatic arthritis. The drug is a PEGylated Fab'part of a humanized monoclonal antibody specific to TNF-α. The attachment of polyethylene glycol to the antibodies aims at increasing the drug's half-life and masking the drug epitopes, hence evade the immune system and minimize the drug immunogenicity.
Moreover, unlike other iTNF, the monoclonal antibody lacks the Fc region to prevent both: the activation of complement system and the antibody-dependent cell-mediated cytotoxicity (Acosta-Felquer, Rosa, & Soriano, 2016) .
The production of ADAs against etanercept is a rare event.
Should they be present, they lack neutralizing effect and thus have no influence on the clinical response of the patient (Garceŝ et al., 2013; Hsu & Armstrong, 2013; Lambert et al., 2015) . For this reason, in patients with secondary failure to treatment, the estimation of ADAs levels against monoclonal antibodies (infliximab or adalimumab) could be of particular use.
| CONCLUSIONS
TNF-α inhibitors can induce formation of ADAs although monoclonal antibodies are more immunogenic than the fusion protein (etanercept). The reason for the fading of a treatment response with iTNF-α in patients with psoriatic arthritis and other autoimmune diseases is a multifactorial mechanism. The immunogenicity may affect drug pharmacokinetics, which would lead to hampering the clinical response so a need to increase the drug dose arises (Bartelds et al., 2011) .
Although the estimation of serum ADAs and drug levels is not a routine in clinical practice, it is of paramount importance to keep in mind that neutralizing ADAs remain at the centre of biologic drug secondary failure, which may be particularly significant in patients not exposed to such treatment before. In order to defer the formation of ADAs and avoid switching to a new drug, hence new immunization, it is advised to use proper doses, plan the treatment in the long-run and use an immunosuppressive adjuvant even if not recommended otherwise.
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